

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number
WO 2022/024072 A1

(51) International Patent Classification:

A61K 31/13 (2006.01) *A61K 31/473* (2006.01)
A61K 31/27 (2006.01) *A61K 31/55* (2006.01)
A61K 31/445 (2006.01) *A61K 45/06* (2006.01)
A61K 31/47 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/IB2021/056986

(22) International Filing Date:

30 July 2021 (30.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202021032951 31 July 2020 (31.07.2020) IN

(71) Applicant: **SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED** [IN/IN]; 17B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (E), Mumbai, Maharashtra 400093 (IN).

(72) Inventors: **DAMLE, Nitin Krishnaji**; Beach House CHS, E8, 8th Floor, Gandhigram Road, Juhu, MUMBAI, MAHARASHTRA 400049 (IN). **MANDHANE, Sanjay Nandlalji**; 79, Pratham Enclave, Sun Pharma Road, Vadodara, Gujarat 390012 (IN). **SONI, Durgesh Ashokkumar**; D-121, Vrundavan Township, Makarand Desai Road, Vadodara, Gujarat 390007 (IN). **JAIN, Shakti Kamalchand**; A-403, Velani Heights, Sun Pharma Road, Vadodara, Gujarat 390012 (IN). **RAMANATHAN, Vikram Krishna**; "Parvati", Near Azad Society, Ambawadi, Ahmedabad, Gujarat 380015 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: *N'*-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL) ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE

(57) Abstract: The present invention provides a method for preventing or treating Alzheimer's disease and symptoms thereof comprising administering to a subject in need thereof a therapeutically effective amount of *N'*-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or a its pharmaceutically acceptable salts, wherein the prevention and/or treatment of said disease and symptoms thereof is achieved by inhibition of amyloid-beta ($A\beta$) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof. Also disclosed is the use of a therapeutically effective amount of *N'*-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or its pharmaceutically acceptable salts to inhibit amyloid-beta ($A\beta$) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof.



WO 2022/024072 A1